Kevin Koch sold $107k of EWTX
President and CEO at Edgewise Therapeutics, Inc.. 7,972 shares at an average of $13.39, traded Aug 12, 2025, filed Aug 14, 2025.
Score components
- +25RoleCEO
- +10Trade size$107k at market
- +5Share of holdings soldSold 21% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-005795, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2025 | MOption exercise Common Stock | +17,968 | $0.00 | $0 | 38,587 | Aug 14, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock | -7,972 | $13.39 | $107k | 30,615 | Aug 14, 2025 |
| Aug 12, 2025 | MOption exercise Restricted Stock Unitsderivative | -17,968 | $0.00 | $0 | 53,907 | Aug 14, 2025 |
| Aug 12, 2025 | AGrant or award Restricted Stock Unitsderivative | +87,500 | $0.00 | $0 | 87,500 | Aug 14, 2025 |
| Aug 12, 2025 | AGrant or award Stock Option (Right to Buy)derivative | +525,000 | $0.00 | $0 | 525,000 | Aug 14, 2025 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $1.5M 100,000 shares | -81% | |
| 22Weak | Edgewise Therapeutics, Inc. | R Michael Carruthers Chief Financial Officer | $19k 1,428 shares | -2% | |
| 21Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $33k 2,491 shares | -10% | |
| 26Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $38k 2,862 shares | -10% | |
| 20Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $26k 1,907 shares | -8% | |
| 25Weak | Edgewise Therapeutics, Inc. | John R Moore General Counsel | $28k 2,098 shares | -17% | |
| 22Weak | Edgewise Therapeutics, Inc. | R Michael Carruthers Chief Financial Officer | $22k 1,314 shares | -2% | |
| 20Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $28k 1,691 shares | -8% | |
| 29Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $85k 5,187 shares | -19% | |
| 38Weak | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $70k 4,276 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.